Skip to main content
Clinical Trials/NCT05752383
NCT05752383
Recruiting
N/A

The Clinical and Hemodynamic Course of Cardiogenic Shocks Hospitalized in Critical Care

Centre Hospitalier Universitaire, Amiens1 site in 1 country500 target enrollmentJanuary 24, 2023

Overview

Phase
N/A
Intervention
Not specified
Conditions
Cardiogenic Shock
Sponsor
Centre Hospitalier Universitaire, Amiens
Enrollment
500
Locations
1
Primary Endpoint
Percentage of in-hospital mortality after cardiogenic shock
Status
Recruiting
Last Updated
3 years ago

Overview

Brief Summary

Cardiogenic shock is a frequent reason for hospitalization in critical care units, with high mortality (50%). Several French registries have been created to improve knowledge of the prognostic factors of cardiogenic shock. In recent years, temporary mechanical circulatory support has become more important in cardiogenic shock. The monitoring of catecholamines is also performed with a global score: the vaso-inotropic score. The purpose of our study is to consider using these new data and techniques to create a cohort of cardiogenic shock within our critical care unit.

This observational study is based on clinical, biological, and hemodynamic data recorded during the ICU stay of patients for cardiogenic shock.

The primary endpoint is the relationship between the hemodynamic evolution of cardiogenic shock and in-hospital mortality.

Registry
clinicaltrials.gov
Start Date
January 24, 2023
End Date
January 2029
Last Updated
3 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patients hospitalized in ICU for cardiogenic shock
  • Patient with cardiogenic shock as defined by the FRENSCHOCK2 study criteria

Exclusion Criteria

  • Patient with cardiogenic shock in the context of septic shock and hemorrhagic shock

Outcomes

Primary Outcomes

Percentage of in-hospital mortality after cardiogenic shock

Time Frame: 5 years

Vaso-inotropic score after cardiogenic shock

Time Frame: 5 years

vasoactive-inotropic score (VIS) Maximal VIS (VISmax) is calculated using the highest doses of vasoactive and inotropic medications administered. VISmax categories: 0-5, \>5-15, \>15-30, \>30-45, and \>45 points.

Study Sites (1)

Loading locations...

Similar Trials